Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

KYTH 0.0000
price chart
Why Kythera Biopharmaceuticals, Inc Rocketed Higher
What's happening: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) soared higher by as much as 20% ahead of a key FDA advisory panel committee meeting next week.
FDA Staff Backs Injection To Reduce Double Chin  Medical Daily
Come This May Double Chins Will Be History, Kythera  Empire State Tribune
Why Kythera Biopharmaceuticals, Inc. Stock Soared Today
What: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) shot up by 22% today after the company agreed to sell itself to Botox-maker Allergan (NYSE:AGN) for $75 per share, or $2.1 billion.
Allergan to Acquire KYTHERA Biopharmaceuticals  PR Newswire (press release)
Why KYTHERA Biopharmaceuticals Inc. Shares Shot Higher
What: Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH), a clinical-stage biopharmaceutical company developing prescription products targeted at the aesthetic medicine market, jumped by as much as 12% after the company announced it had ...
Kythera Regains ATX-101 from Bayer  Zacks.com
Kythera Buys Back Double Chin Candidate from Bayer  Genetic Engineering News
Related articles »  
KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM) -- First ...
WESTLAKE VILLAGE, Calif., June 19, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the U.S.
Kythera Biopharmaceuticals Stock Climbs On Acquisition News  CNA Finance (press release)
Kythera Biopharmaceuticals Inc's (KYTH) Double-Chin Treatment Backed By FDA Panel
Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) announced Monday that its double-chin treatment has won the backing of a US Food and Drug Administration (FDA) advisory panel which unanimously voted to recommend the final approval of the injectable ...
Sell Kythera (KYTH) Stock, Another Biotech Ripoff  Investorplace.com
Why Keith Leonard Unloaded 3500 Shares of Kythera Biopharmaceuticals Inc ...
In view of the deal Keith Leonard made he is in the bear's eye today. The President & CEO of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) 0.0000 0.00 % and an insider, made a sale of 3,500 shares worth $175,151 USD. The average price was $50.0 ...
Allergan (AGN), KYTHERA Biopharma (KYTH) Enter Amended Merger; Will Now be All ...
Allergan (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to ...
Allergan Changes Its $2.1 Billion Deal for Kythera to All Cash  Wall Street Journal
Allergan reports better-than-expected revenue  Reuters
Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA ...
WESTLAKE VILLAGE, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced today that the U.S.
FDA approves Westlake Village company's drug to reduce double-chin fat  Los Angeles Times
Kythera Wins FDA Approval for Double-Chin Treatment  Wall Street Journal
Reasons for Keith Leonard's Shares Sale of Kythera Biopharmaceuticals Inc ...
13,548 shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) 0.0000 0.00 % were unloaded by Keith Leonard, the corporation's President & CEO.
What Hedge Funds Think About Kythera Biopharmaceuticals Inc (KYTH)
According to our 13F database, Partner Fund Management, managed by Christopher Medlock James, holds the biggest position in Kythera Biopharmaceuticals Inc (NASDAQ:KYTH). Partner Fund Management has a $30.2 million position in the stock, ...
Related articles »